Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection

AIM: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. METHODS: Using established kinetic data for [(177)Lu]Lu-DOTA-TATE and [(177)Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Verburg, Frederik A., de Blois, Erik, Koolen, Stijn, Konijnenberg, Mark W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638215/
https://www.ncbi.nlm.nih.gov/pubmed/37947917
http://dx.doi.org/10.1186/s40658-023-00589-w
_version_ 1785133558785900544
author Verburg, Frederik A.
de Blois, Erik
Koolen, Stijn
Konijnenberg, Mark W.
author_facet Verburg, Frederik A.
de Blois, Erik
Koolen, Stijn
Konijnenberg, Mark W.
author_sort Verburg, Frederik A.
collection PubMed
description AIM: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. METHODS: Using established kinetic data for [(177)Lu]Lu-DOTA-TATE and [(177)Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([(177)Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [(177)Lu]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161. RESULTS: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617. CONCLUSION: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.
format Online
Article
Text
id pubmed-10638215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106382152023-11-11 Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection Verburg, Frederik A. de Blois, Erik Koolen, Stijn Konijnenberg, Mark W. EJNMMI Phys Short Communication AIM: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. METHODS: Using established kinetic data for [(177)Lu]Lu-DOTA-TATE and [(177)Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([(177)Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [(177)Lu]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161. RESULTS: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617. CONCLUSION: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits. Springer International Publishing 2023-11-10 /pmc/articles/PMC10638215/ /pubmed/37947917 http://dx.doi.org/10.1186/s40658-023-00589-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Verburg, Frederik A.
de Blois, Erik
Koolen, Stijn
Konijnenberg, Mark W.
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
title Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
title_full Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
title_fullStr Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
title_full_unstemmed Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
title_short Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
title_sort replacing lu-177 with tb-161 in dota-tate and psma-617 therapy: potential dosimetric implications for activity selection
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638215/
https://www.ncbi.nlm.nih.gov/pubmed/37947917
http://dx.doi.org/10.1186/s40658-023-00589-w
work_keys_str_mv AT verburgfrederika replacinglu177withtb161indotatateandpsma617therapypotentialdosimetricimplicationsforactivityselection
AT debloiserik replacinglu177withtb161indotatateandpsma617therapypotentialdosimetricimplicationsforactivityselection
AT koolenstijn replacinglu177withtb161indotatateandpsma617therapypotentialdosimetricimplicationsforactivityselection
AT konijnenbergmarkw replacinglu177withtb161indotatateandpsma617therapypotentialdosimetricimplicationsforactivityselection

Ejemplares similares